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Abstract
Observational studies and clinical trials have become increasingly important over
recent years and play an essential role in advancing medical knowledge. In today’s
world of clinical research, it is not possible to imagine trials without the founda-
tion of a well-established it-infrastructure. Electronic capture and usage of data is
pervasive.
In practice, medical progress requires the ability to integrate data from different
systems. An essential factor in enabling different actors, such as institutions and
hospitals, to have their systems exchange structured data and make use of the
information is the interoperability of the data and systems.
FHIR (Fast Healthcare Interoperable Resources) is a free and easily customizable
HL7 platform standard, based on 30 years of experience of HL7. It is focused on
providing health-related information and defines a set of capabilities used in the
health care process.
This thesis will provide a conceptual approach for working with FHIR, as well
as concrete approaches for working with FHIR profiles and for customizing the
standard for particular use cases. It will be carried out in cooperation with the
Medical Systems R&D, which is a service provider within the University Hospital
of Cologne.
The guiding request approach will focus on the evaluation of requirements for clini-
cal trials and how clinical research protocols can be represented in an interoperable
and machine-parsable format using FHIR.
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Interoperability; FHIR; Medical Knowledge; Health Care; Clinical Trials; Research
Protocols
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1. Introduction
1.1. Motivation
Over the last years, health care providers have come under increasing pressure to provide
a better service at lower costs. Compensation is increasingly based on treatment-quality
and results (Pay4Performance). At the same time, innovative therapies involve highly
specialized testing and continuous intersectoral documentation.
While only a few years ago, the primary goal of medical documentation was to satisfy
legal requirements, today the goal of data-driven treatment is of at least of equal impor-
tance. Also, an increase in clinical research, in the interest of the patients, is placing new
requirements on the quality of medical documentation.
Innovative therapies involve personalized and genomic medicine which take into account
a vast amount of data a specialized documentation which has to be linked up to routine
documentation in the Electronic Medical Record. [1]
However, present clinical systems and the routine data collected don’t have the quality
needed to ensure a safe therapy assessment or to support prospective long-term studies.
This is the reason why individual and highly specialized systems are evolving. These
Systems, however, do not integrate well with the primary systems. This is due to the
high barrier in supporting legacy interoperability standards but also due to the fact that
these standards do not yet support the semantic models for these innovative new domains.
The electronic medical record is highly fragmented, and the user needs to access multiple
decoupled systems. Solutions using a typical data warehouse are a possible approach to
integrate the data, but it still doesn’t help the challenges regarding the quality of data
because optimal documentation can only be achieved in the clinical context. [2]
Additionally, data warehouse approaches have proven to be expensive in acquisition, es-
tablishment, and maintenance. The costs for IT are high since new interfaces have to
implemented and maintained constantly and consistently. For medical personnel, the
effort is high too, since the data has to be transformed outside of the clinical context.
Based on the insight, that the quality of data and the efficiency in its aggregation is
dependent on its integration of clinical processes, a solution for a better documentation
can only be reached in the clinical context.
A prerequisite towards this goal is standardization of data, transport-formats and appli-
cation interfaces.
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Such a standard is the Fast Healthcare Interoperability Resources standard (in short
FHIR) which is currently emerging internationally and has gained high popularity. It is
created, published and maintained by the HL7 community [3].
The integration, described above, and the structured input and output are made possible
by this standard. It combines format, transport, and interfaces into a framework, that is
still compatible with other protocols, such as HL7 v2 and IHE.
FHIR is bringing to health care a paradigm shift, from document-centered approaches to
direct access to granular data fields. ”FHIR represents clinical data as resources, where
each resource is a coherent expression of meaning stated in terms of well-defined fields and
data types.”. [4, p.900] An essential goal of FHIR is, to enable the processing of health
care data on mobile devices such as smartphones and tablets and to integrate them with
existing systems.
The FHIR Standard builds on existing web-based interfaces and provides security mech-
anisms, to accomplish the high data safety and privacy requirements needed in health
care.
This technology is enabling the granularity and quality needed for data-driven clinical
decisions and innovative clinical research.
1.2. Research Approach
The main goal of this thesis is to develop an approach where researchers can move on
from writing clinical protocols in a document-centered format to a format which is directly
accessible in a machine-readable pattern.
The advantages are numerous. For one, the protocols - which could be highly complex -
can be validated to avoid costly inconsistencies. Also, they could be deployed in various
systems for different purposes - for instance, monitoring compliance or planning treatment
schedules at the study site.
To give some insight into the complexity of a study protocol we consider the following:
Patients will be recruited in a time frame of 6 to 12 months depending on how difficult
it would be to reach the sample size for the trial. The visit schedule would be defined for
each patient relative to their date of enrollment. Any delay in the treatment would - from
the point of view of the trial - only be tolerable to a certain extent. If the subject has an
infection or any other adverse event, one would have to wait until the study subjects are
in a state to continue treatment with the investigational drug. Within a tolerable delay,
you would reset the schedule for the following visits relative to that delay.
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The delay has a tolerable range ”Allowable Window”: if the patient delays too long -
depending on the trial - they’d would fall out for the major statistical analysis and would
remain in the trial with the ”Intent to Treat”. The allowable windows of delay in the
schedule may be different for each investigational drug in the same trial.
Treatment noncompliance may have consequences for the further treatment. For example,
it would possibly no longer make sense to have the patient endure a painful bone marrow
biopsy at final assessment (last visit of the treatment phase) once the patient is no longer
fully compliant with the regimen/study protocol.
Presently systems have to model and calculate the allowable windows for all visits within
the individual applications for each trial. It would make sense for the researcher writing
the protocol to publish that data in FHIR for systems to import and avoid the burden
and possibility of errors.
1.3. About the Medical Systems R&D group
The Medical Systems R&D group, supporting this thesis have cooperated with the author
by sharing their knowledge and previous work. Medical Systems R&D is a research group
and service provider for clinical research at the university hospital in Cologne.
The history of the group was from my point of view fascinating because it gave me insight
into what it takes to set up a group to develop qualified medical software from scratch.
Information used for this chapter were obtained in personal communication. [5]
The group was set up in 2010 as a joint group of the Clinical Trials Center Cologne and
the German CLL Study Group with the purpose of developing innovative software for
conducting clinical trials. To ensure software qualification, a joint structure was required,
and it was agreed that an informal joint group would be set up.
A Quality Management System (QMS) was set up with the help of external consultation.
An employee dedicated to Requirements Management (REQM) and Software Quality
Assurance (SQA) was engaged in 2011. In line with the goals of all parties to conduct
high-quality clinical research, the envisaged systems were originally planned to satisfy the
following quality requirements:
• ICH Topic E6, Guideline for Good Clinical Practice, 1997
• German Pharmaceutical Law, AMG, implementing GCP-V, 2004
• Laws on patient data protection and personal data privacy (Datenschutzgesetz
Nordrhein-Westfalen - DSG NRW) as per bulletin of 9th of June 2000
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The development and system specifications have in the course of the project also taken
the following guidelines into account:
• 21 CFR part 11
• European Medicines Agency, Reflection Paper on expectations for Electronic source
data transcribed to electronic data collection tools in clinical trials, 2007
• FDA, General Principles of Software Validation, Final Guidance for Industry and
FDA Staff, 2002
• FDA, Guidance for Industry, Computerized Systems Used in Clinical Investigations,
2007
• Martin and Perez, GAMP 5 Quality Risk Management Approach, 2008
• Eudra Lex, Volume 4, Good Manufacturing Practice, Annex 11: Computerized
Systems, 2011
• Relevant QM- and Process-Management norms such as ISO 9000, ITIL
The setup of the new group and processes led to the successful development of a pilot
version of a Clinical Data Management System in December 2011, a successful vendor
audit in April 2012 and a production release of a basic GCP compliant system in May 2013.
A successful User Acceptance Test (UAT) by DCLLSG led to the formal commissioning
of the system for the CLLM1 Trial in June 2013. An informal charter was set up in 2011.
It has been elaborated on overtime by the feedback of stakeholder meetings/executive
meetings.
Systems R&D pursues the primary purpose of developing innovative systems and services
to support clinical research. To this goal, a set of fundamental values was defined. Quality
and usability standards will be of utmost importance and will drive all work SRD sets
out to engage in. SRD also strongly believes in a close relationship with the individuals
and institutions commissioning and using its systems or services. It considers the rela-
tionship to be its major asset and will continuously strive to strengthen this relationship
by anchoring it in its processes and strategies. Accountability and a focus on solutions
are part of this strategy.
The primary stakeholders, Michael Hallek and Oliver Cornely, themselves deeply engaged
in clinical research, have set up the group committed to the stated values and have
entrusted their research and funds in the ability of the group to perform on these values.
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1.4. Structure of the Thesis
The Thesis starts off with a theoretical explanation about interoperability in the spe-
cific context of FHIR (chapter 2.1). The different stages of interoperability follow an
introduction to the history of HL7 (chapter 2.2). Different examples and the concrete
meaning of each layer in FHIR are given; focused on building a general understanding of
interoperability and the possibilities it enables.
This is followed by an insight into clinical studies and clinical protocols (chapter 2.3). The
focus here is set on the techniques and procedures of Systems R&D, even though these
principles and technologies are found in similar ways in other companies and institutions;
meaning they can be generalized to a certain point as well.
Clinical trials are a very complex subject, and different aspects can be discussed. Since
this thesis can’t cover all possible points, the explanations are limited to the sections
which are necessary for understanding the approaches described.
The customizability of FHIR is shown, starting with an explanation of the hierarchy of
resources (chapter 3.1.2), followed by limits and scopes of profiling (chapter 3.2). This
includes some central aspects of profiling but does not cover all possible aspects. The
approach taken is to build FHIR profiles, based on the standard patterns used in clinical
care and extend these to be able to cover clinical protocols (chapter 5). This approach
is discussed and applied with the background knowledge and infrastructure of Medical
Systems R&D. Even though the technical approaches and the Systems are internal and
protected, the FHIR profiles are free to use and can be taken into consideration for further
strategies.
The thesis finishes off with an explanation of the lessons learned during the project (chap-
ter 6.1). Including the positive and negative aspects, as well as a personal opinion of the
author. A final future outlook wraps up the thesis and shows the possibilities for contin-
uing the project and creating machine-readable clinical trial protocols (chapter 6.2).
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2. Theoretical Background
This background is intended to provide a basis for understanding the context and solution
approaches which have been elaborated on as part of this thesis. It deals with the origins
of interoperability, and the standards organization HL7, as well as HL7 FHIR and its
origins.
A considerable challenge these days is the communication between different Stakeholders
in health care and their respective systems. As electronic data and health care IT Systems
have become highly specialized in the recent years, various stakeholders have developed
their technology in an isolated way. The different Systems have continued to exist and
evolved independently, creating a communication gap. [6] Most recently, the focus has
shifted to integrating these specialized systems with the electronic health record (EHR).
Interoperability is the technical solution for this communication gap. There are various
reasons for making an effort to achieve interoperability in health care. These reasons
include, but are not limited to:
1. Less burden and improved patient satisfaction, avoiding unnecessary double testing.
2. Faster diagnostics using data from different institutions in aggregated and possibly
filtered form; resulting in less manual work for the practitioner.
3. An overall better general view of the patient’s clinical data, resulting in higher
clinical safety
Consequently, if no interoperability is achieved, harmful and risky situations can arise in
the clinical context, which in the best case would only lead to significantly higher costs,
in the worst case to wrong treatment decisions. [7]
It is often stated in the literature, that a patient should not only be seen as an expense
factor but that the focus and attention should be on achieving a ”value” for the patient.
[8]
To realize this up to a certain level, different layers of interoperability which build upon
each other have evolved. [9] A more detailed explanation of the different layers can be
found in chapter 2.1.
Since the goal is to work out a feasible connection between FHIR and research protocols,
this chapter as the thesis in general mainly focuses on Fast Healthcare Interoperable
Resources (FHIR). It is an evolving Standard, and Systems R&D has as of adopted the
use of FHIR in their Systems over the last year an a half. A more detailed overview of
FHIR is given in Section 2.2.
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Also, some background on clinical trials and how they are conducted on clinical sites will
be necessary (Section 4).
Here, we will focus on a subset of the clinical protocol data based on concrete examples
in projects of Systems R&D and the University Hospital Cologne.
The University Hospital of Cologne historically has a strong focus on Clinical Trials. It
hosts the oldest Academic Study Group in Germany - the German Hodgkin Study Group
(GHSG) and the very successful German CLL Study Group (GCLLSG) [10]. The hospital
is one of the primary study sites in Germany conducting up to 700 clinical Trials per year
[11].
2.1. Interoperability
A central element in the digital world of health care is the possibility of sharing data
and information in a timely and secure manner between patients, hospitals, dispensaries,
health insurances and other clinical institutions. However, the present electronic exchange
of information doesn’t provide this kind of communication. A prerequisite is that the
sender and receiver both understand the data and can process the information.
To accomplish this, multiple international standards have evolved in the recent years. A
few examples are SNOMED CT, HL7, HL7 FHIR, DICOM and LOINC [12].
The ability to exchange and share information in health care is often seen as ”essential
to facilitate the quality and effectiveness of health care services” [13] Interoperability is
often referred to as the ability of different systems to exchange data and use information
that has been transferred. HIMSS states ”Interoperability means the ability of health
information systems to work together within and across organizational boundaries to
advance the health status of, and the effective delivery of health care for, individuals and
communities.” [14]
Another common definition for Interoperability is the ”ability of two or more systems or
components to exchange information and to use the information that has been exchanged”.
[15]
In practice, this would, for example, mean that observations of a patient made at a
specialists practice can be transferred to a hospital and be processed further, for example
in the ”electronic medical record” (EMR) of that hospital.
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In general terms, different steps have to be fulfilled, if a system wants to be interoperable.
These steps might seem trivial but are necessary to construct an interoperable digital
medical record. [16]
1. The medical information needs to be represented in a digital form, to enable a
lossless electronic transport of the data.
2. The Electronic Health Records (EHRs) need to have the capability to transfer the
information to other systems digitally.
3. The receiver of the information must be capable of understanding and processing
the information, as well as integrating multiple records. [16]
The Article of Diameter Health states further that the third step of achieving interoper-
ability is the hardest since it deals with semantic interoperability. It is one of the layers
that are commonly used to classify interoperability. However, there is no consensus about
the number of levels. Some authors define three; others chose a four or higher tier model
(figure 1). [17] [18]
We can take HL7 FHIR as an example to show the defined levels of interoperability.
Figure 1: Levels of interoperability (adapted from [19])
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1. Technical / Foundational interoperability
Technical Interoperability is often called Foundational Interoperability. It refers to
the connectivity between the communication and information systems, which are
involved in the exchange of data. It describes the possibility to build a network of
systems, based on a chosen communication protocol. [20]
2. Syntactical interoperability
As a verification of the structure, syntactical interoperability can be taken into
account. It can be described as a model, that can be used to measure if specific
aspects of the data are encoded correctly. The validation can include content, data
types and other validation rules. [21]
3. Semantical interoperability
As opposed to other domains, such as banking, where the resources are quantifi-
able, and the information is highly structured, health care data most likely isn’t.
Physicians may document the same analysis in different ways. Coding Systems like
SNOMED CT1 can help to achieve semantical interoperability since the descriptions
can be done through code instead of free text. [16]
4. Organizational interoperability
The highest level of interoperability is the so-called, organizational Interoperability.
It facilitates the integration of business processes, as well as workflows beyond the
boundaries of a single organization. It, however, needs a high level of commitment,
since it requires the other three levels to collaborate. [13]
To sum up, it can be stated, that interoperability enables more efficient access to patient
information and it can reduce the redundant collection of health care data [22].
Though many different standards can be used to achieve a defined level of interoperability,
FHIR is the one that is focused on in this thesis. Systems R&D sees this standard as a vital
step in bridging Clinical Research with Health care - domains which are today highly split
causing unnecessary financial burden and slowing turnaround in clinical research. Several
important companies such as Google [23], Apple [24] and Microsoft [25] have just recently
adopted the standard.
1SNOMED is an international coding system about health care data, more information at
https://www.snomed.org
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2.2. FHIR
In the following Subchapter, Fast Healthcare Interoperable Resources (FHIR) is explained
in further detail. We will do so sufficiently as to provide the necessary context for the con-
cepts discussed in the thesis. In essence, the capabilities of customizing existing resources
(chapter 2.2.2) will have to be understood in sufficient detail.
For completeness, at the time of this thesis the applicable FHIR release is version 3
(Standard for Trial Use). Therefore, all explanations refer to this version. Experimental
work on future versions will be referred to in the future outlook section (chapter 6.2).
2.2.1. History of HL7 and FHIR
The HL7 Organization, the publisher of FHIR, dates back to the late 1970s. The Univer-
sity of California first published it in San Francisco (UCSF). HL7 v1 and v2 are sometimes
called refinements of the UCSF protocol [26].
A big issue at the time was that all interfaces between systems were exchanging data using
custom solutions. Each of them designed individually and the sending and receiving of
data resulted in manual work on each side of the sender and receiver [27].
Solving this problem by using a standard in health care, it was deemed essential to
determine stakeholders, who have an interest in the whole system. In the Context of
HL7, different user types have emerged. These users have an equal influence on how a
standard is developed and used in health care. These three groups are actively interested
in HL7 Standards and can be described as follows [27]:
1. Clinical interface specialist
This user group is responsible for transferring data between different institutions.
They are tasked to move the clinical data or create clinical applications for exchang-
ing data with other systems.
2. Government or other politically homogeneous entities
The biggest interest here is the future of sharing data across different institutions.
Sometimes this group is even looking to move data into new fields, which are not
yet covered by an interoperable working system.
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3. Medical Informaticists
Are working in the field of health informatics. This group seeks to understand
clinical knowledge and build up an ontology2. This persona is interested in the
general representation, semantic interoperability and the modeling of actions and
actors in health care.
Figure 2: Timeline of HL7 Standards [28, p.17].
Licensed by CC BY 3.0
The HL7 v2 Standard was initially published in 1989 after a proof-of-concept completed in
1987 [29]. This Version sets the focus on the exchange of data through, so-called segments.
They can be described as an ordered amount of data elements, used to transfer a bundle
to a specified receiver.
A message in HL7 v2 has a concrete message type; besides, it is encoded by a specific
message syntax table, which contains the metadata for the individual model. One single
line of a message is called a segment. Taking the PatientName as an example, it is placed
at the 5th position of PatientIdentification Details segment. The delimiters that separate
different elements can determine the position. [18]
HL7 v2 is still widely in use, however, to help FHIR spread and evolve further, HL7
has provided mapping tables from different standards (including v2) to FHIR (table 5).
Quoting Dr. Frank Oemig, a Senior eHealth Architect at Deutsche Telekom Healthcare
and Security Solutions GmbH in Mülheim, a leading expert on HL7 V2:
HL7 v2 ist derzeit noch der am weitesten verbreitete Standard, er entwickelt sich
konstant weiter und wird noch mindestens die nächsten 10 Jahre weiter genutzt. [30]
-
HL7 v2 is still the most used standard. It is constantly evolving and will be used for at
least ten more years (free translation by the author of this thesis)
2A hierarchical structure, representing the knowledge about health care
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Resource field v2 Code
identifier PID-3
active
name PID-5, PID-9
telecom PID-13, PID-14, PID-40
gender PID-8
birthDate PID-7
deceased[x] PID-30 (bool) and PID-29 (datetime)
address PID-11
maritalStatus PID-16
... ...
Table 1: Mappings for v2 to FHIR of the Patient Resource (adapted from [31])
Due to the high success of HL7 v2, the foundation decided to develop HL7 v3, as a direct
successor. In addition, the Clinical Document Architecture (in short CDA) was created.
In detail, CDA is a XML-based markup standard with the intend to specify encoding,
structure and semantics of clinical documents, in order to exchange them. Both of those
standards follow a model-driven design approach.
One of the most significant drawbacks in HL7 v2 is related to the missing information
model that supports the structured and semantical setup of the messages. [32] [33] This
results in the lack of possibility to represent some concepts such as medications and clinical
workflows.
HL7 states, however, that the V2.x series of messages were widely successful and widely
implemented. In fact, it’s widespread use might also be the reason why V3 never took
off. [34]
The Version 3 Normative Edition represents a new approach to clinical information
exchange based on a model-driven methodology that produces messages and electronic
documents expressed in XML syntax. [34]
Based on the RIM (Reference Information Model), the HL7 v3 Data Specification and
the Vocabulary Specification, the information can be exchanged using the self-contained
clinical documents (Clinical Document Architecture - CDA) or the XML-based messages
of HL7 v3.
Due to the complexity of the HL7 v3 model, HL7 set out to create a new approach of
using Resources. This provided the initial and fundamental concept for FHIR as it is
right now. [35]
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2.2.2. Layer of Interoperability in FHIR
As previously mentioned, FHIR is split into four different layers of interoperability (figure
1). FHIR describes their level of interoperability, without using the exact terms (technical,
syntactical, semantical and organizational interoperability) (figure 3).
Figure 3: Layer of Interoperability in FHIR
Mapping the mentioned Levels of FHIR onto the four Layers of interoperability, we start
with ”Level 1 Basic framework on which specification is built”. This Level represents
the technical interoperability, providing the necessary connectivity between the different
systems. In FHIR the ”Foundation Module” is responsible for the running infrastructure.
[36]
Different techniques can be used to exchange the information on a technical Level. FHIR
specifies four technologies:
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1. RESTful API
Most implementers are deciding to use the RESTful API as the connectivity method
of their choice. According to the FHIR specification, it follows the principles of
RESTful design for ”Creating, Reading, Updating and Deleting” (CRUD-operations).
[36]
Though HL7 states, that FHIR is only supporting Level 2 of the REST Maturity
model3, Level 3 can be achieved through extensions. [37]
Rest is performed in general directly through HTTP request and responses on the
server. A few examples of different REST API calls in FHIR can be found in the
appendix A.
2. Messaging
The Messaging paradigm can be implemented using the RESTful API but also
using any other form of a messaging stack. It allows the exchange of data using
routing messages. Messages are triggered exclusively by clinical events, defined in
the FHIR-Standard. They consist of a MessageHeader which indicates the type of
the event, such as the destination of a possible response. The concrete procedures
are not explained further at this point, because they are neither focus of, nor are
they relevant for this thesis.4[38]
3. Documents
FHIR defines a computer-assisted human to human communication framework, to
support the universal fact of having a human reader to communicate. To help ensure
the confidentiality and the accuracy of the document, FHIR provides the possibility
to create immutable versions of the report to work with5.[39]
4. Services / SOA
It has to be stated that all the alternatives above are ”services” in some definition.
SOA doesn’t refer to an exchange format itself but indicating that basically, all
exchange methods conform to the FHIR standard, as long as the exchanged data
contains valid FHIR resources as in definition. Concluding, the FHIR-Specification
allows and supports services like SOA to exchange data in the form of valid FHIR
resources.[40]
3Further Information about the Maturity Model of the REST API can be found at
https://martinfowler.com/articles/richardsonMaturityModel.html, written by Martin Fowler
4Further information about the messaging using FHIR Resources can be found here
https://www.hl7.org/fhir/messaging.html
5Further information about the FHIR Documents can be found here
https://www.hl7.org/fhir/documents.html
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To support the syntactical interoperability, FHIR uses a conformance statement. This
module represents metadata about the datatypes and resources used. The conformance
resource contains two different statements. On the one hand, the ”ImplementationGuide”
describes a set of rules that are used to solve a particular problem. The CapabilityState-
ment, on the other hand, can be described as a list, containing all the capabilities the
FHIR-Server is supporting. [41]
According to the FHIR-Specification, the Server shall return the conformance resource on
getting the particular request for it; displayed by the following URL.
http://providerserver/fhirbase/metadata
In this case, ”providerserver” is a placeholder for the URL of the provider and ”fhir-
base” is representing the FHIR-Endpoint of the server. Calling metadata returns the
Conformance-Statement, making it possible for external health care applications to auto-
matically adjust their functions and capabilities to the ones of the FHIR-Server they are
connecting with. [41]
An example Conformance Statement can be found in the appendix B.
Figure 4: Components of a FHIR Resource [42]
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The internal build of a FHIR Resource (figure 4) can be divided into different parts.
1. Metadata
Metadata generally provides information about the content of an item. [43]
In FHIR, Metadata contains the literal identity in the form of a URL and the date
where the resource was last updated.
2. Narrative
The narrative describes a representation of the resource that is human-readable.
This is done to provide a base-level of interoperability since this representation of
a resource should also be interpreted by a human.
3. Elements & Extensions
Elements and Extensions are the part representing the actual data in FHIR. All
necessary information is described in these sections of a resource. The Elements
themselves are a normative part of in the standard, while the Extensions can be built
individually by vendors or interested parties developing their specialized domains
and applications. Further information on Extensions is given in chapter 3.
A single FHIR Resource itself can sometimes be not enough to represent the data needed
for a certain Use-Case. To help this, FHIR provides the possibility to build up bundles
of resources, linked by their literal or logical reference. Upon creation of a resource, the
logical id is returned in the form of a Uniform Resource Identifier (URI). A resource
should be obtainable by this URI, depicted in figure 5.
Figure 5: Linking FHIR Resources with Identifiers [42]
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Building up a semantical understanding is fundamental in providing interoperability since
the receiver of a message needs the ability of processing and understanding the message
in a way, the sender intended (figure 6). To prevent misunderstandings, Coding-Systems
like SNOMED CT provide external standardized terminologies. This results in elements,
that are be machin-readable.
Figure 6: Using international Coding-Systems in FHIR [42]
In a specific Use-Case, it can be useful to refer to particular codes of the coding system.
Using a ValueSet in FHIR, allows the possibility to only select out of a list of given codes.
The communication partners can ensure to have the same understanding of a single mes-
sage and process as initially planned.
Lastly, FHIR also specifies Organizational Interoperability. It has to be stated that FHIR
is a ”Platform-Specification”, which means that it enables concrete implementation on an
international level. [44]
With the inclusion of, so-called, extensions and profiling, FHIR can enable cross-organizational
communication on an interoperable level by reducing barriers.
This means that Resources can be modified, as long as the basic rules of the FHIR
specification are matched. This includes cardinalities, data types, and ValueSets. More
Information on organizational interoperability by using profiling is given in chapter 3.
2.2.3. Customizing FHIR to personal needs
Besides the base FHIR specification, which describes a set of resources, frameworks, and
APIs, further adaptations in the form of customization are possible and common practice.
These adaptations can be rules about resources, which define which elements are used and
not used. Also, they can specify additional items added to resources that are not part of
the base specification. [45]
The standard international resources that FHIR offers can be customized to fit the needs
of a specific use case. Standardization in FHIR can be broken down into three different
layers: (inter)national, regional and local levels. [46]
More detailed information about profiling is given in chapter 3.
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2.3. Clinical Trials and Research Protocols
Clinical trials can be described as research studies with the goal of exploring whether a
particular testing method or intervention (be it a medication, a new device or a particular
treatment) is eligible for the medical use on human patients. Trials are one of the final
obstacles, usually after a long process of basic research, in bringing a device or substance
to the market. The process often starts in the laboratory moving on to animal testing
(this phase is called ”pre-clinical research/studies”).
Figure 7: Timeline for the phases of developing a new drug [47]
While human research is needed, because the human follows different pharmacokinetics
and pharmacodynamics than animals, the ”pre-clinical research” can improve the general
safety before the ”clinical trial” begins. Studies are often subdivided into different phases
[47]:
Phase 0: Exploratory IND studies, limited subjects
Phase 1: Early stage of testing
Phase 2: Preliminary safety and efficacy studies
Phase 3: Expanded large-scale studies
Phase 4: Postmarketing studies
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A clinical trial can have different outcomes. It can
1. improve patient outcomes.
2. show no benefit for the patient at all.
3. cause unexpected and potentially dangerous harm for the patient.
All of those outcomes are a potential gain for the trial because the medical knowledge
gathered can advance future tests and improve the patient care. [48] The process of
study and approval can differ between medical drugs and medical devices. The process of
approval can be found in the appendix (appendix C).
Clinical protocols, respectively research protocols are the foundations of every clinical
investigation. They describe in detail how a clinical trial with be conducted. [49] It can
be said, that the protocol specifies the guidelines for conducting the trial. It contains
all the ”metadata” of the study, such as the eligibility of the participating patients, the
timeframe, the test medications and the tests [50].
To date, clinical protocols, are mostly written as a well-structured text document used as
documentation to provide information for the human reader.
However, in the recent years, as protocols have become increasingly complex, they have
come to be seen as a vital source of highly formalized information. [51, 39:10]
The Clinical Data Interchange Standards Consortium (CDISC)6 set out to create the
Protocol Representation Model (PRM) back in 2010, with the goal of information man-
agement and re-use. [51, 40:39]
David Shoemaker (SVP R&D) and Karen Kesler (AVP Operations) name some particular
benefits of PRM. [51, 44:30]
1. to update study summaries automatically
2. transfer of study data into different other systems
3. providing searchable database structures
In the following subchapters, the history of clinical protocols is described in short. Also,
the clinical studies and their typical conduct at the university hospital cologne is taken
into closer consideration.
6A non-profit standards development organization, founded in 1997
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2.3.1. Excursion: Evolution of Clinical Research
A short overview of how Clinical Trials evolved over time gives some insight into how
things evolved to the complex process established to date.
”The charm of history and its enigmatic lesson consists of the fact that, from age to age,
nothing changes and yet everything is completely different” - Aldous Huxley
The first documented event which could be called a clinical trial was in the year 562
BC by the king of Babylon, King Nebuchadnezzar. According to the Bible, specifically
the ”Book of Daniel”, people were ordered to eat meat and drink wine exclusively. As
an outcome of that ”trial” many people died due to the nourishment ordered. [52] In
comparison to of that very early state, clinical studies today are modeled as multiphase
trials where medical treatments and prevention strategies can be conducted. [52]
Another remarkable step was the worlds first documented appearance of placebo. Ac-
cording to medical literature, in 1800. This changed clinical trials because it provided a
solid point of distinction between the two groups of patients where no established stan-
dard treatment is available as reference point. [52] The groups, which patients are set
into, are randomized. This is done since the effect of medication could vary based on the
persuasion of the patient that the substance will work. To prevent the medical personnel
of the study distorting the result by there own bias, even subconsciously, clinical trials are
often set up as double-blinded and randomized. This way, not even the medical personnel
knows which patients are receiving placebo. [53]
The first attempt of a multi-armed study was in 1753 by the British doctor James Lind
who started a trial to cure scurvy. He split twelve sailors into six groups of 2 people each
to give them different food supplement. [53] Clinical Trials practice, as known today, goes
back to 1946. In 1947, the first International Guidance on the topic of ethics in medical
research involving subjects had been formulated in the Nuremberg Code. From that time
onward, the World Medical Association in Helsinki has been articulating principles and
specific guidelines on how human subjects are to be safeguarded in medical research. The
last guideline was published in 2016 (ICH E6 (R2)). [54]
At this point, not all historical events about clinical trials are listed. However, it can be
concluded, that the recent years contained many failures when talking about the ethical
aspects, as well as some success and the will to improve concepts. Even today, researchers
are not always able to prevent all possible harm and research misconducts from the pa-
tients. [55]
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2.3.2. Clinical Studies at the University Hospital Cologne
The University Hospital of Cologne is one of the leading hospitals in Clinical Research.
It hosts the largest clinical trial center in Germany and the comprehensive cancer center
has a very strong focus on clinical research. [56] Besides the oncology department hosts
the two largest academic research groups in Germany. [11]
This has lead to the fact that a convergence of clinical research and healthcare are dedi-
cated focus. Cliniclalsite.org, a service for trial management on study sites, was developed
at the university hospital of cologne and is used by several hospitals in Germany. Also,
Cologne is leading an effort in linking the patient records in the EMR to the research
record of a study subject. FHIR is the technology of choice and Medical Systems R&D
has developed several resources and profiles for this purpose. One essential App developed
there is the Subject Management App which is completely modeled on the ”ResearchSub-
jcect” resource.
Figure 8: Typical state machine for ResearchSubject [57]
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3. Profiling in FHIR
The following chapter aims to provide a general introduction to profiling resources in
FHIR. Covering an introduction to FHIR profiling, including an explanation of the hier-
archical concept of FHIR resources and how the different resources work together. It is
followed by essential techniques and central points to focus on when learning to profile in
FHIR.
The company firely provides a profiling academy on their Simplifier-platform. Information
used in this chapter refers to the provided methods. [46] Another central source is the
FHIR-specification of HL7. [44]
3.1. General information about Profiling
As mentioned before, the FHIR specification describes a set of resources, so-called, base
resources (chapter 2.2.3). However, the wide variability of health care data across different
institution exacerbates the interoperable communication.
”FHIR aims to standardize functionality that is supported by 80% of systems in use” [58]
As a platform-specification, FHIR is neither capable nor aiming to represent a complete
model with the ability of expressing all possible clinical data. It is, however, providing
a foundation to build own implementations on. Customizing FHIR resources enables
stakeholders to add constraints to a resource, to create a profile and form it to their
personal needs.
Since the FHIR standard is designed to build up units of exchange, they need to have a
defined behavior and a known identity. [44] Profiles in FHIR can either extend or restrict
resources in their usage.
Generally profiles are defined using a ”StructureDefinition” resource, as it consists of a
statement of rules about how the different elements are used and where extensions are
used in the resource. [44]
The conformance layer in FHIR gives details about how resources are used to solve partic-
ular use cases. This is done to enable the different applications to exchange data through
the fairly loose structure rules of FHIR.
As a new profile entails creating and defining a StructureDefinition, it may include a
differential-statement, describing the difference towards the base-resource on which the
profile is built on. The full description of the StructureDefinition can be contained inside
a SNAPSHOT. However, both of the variations can be present.
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In the following table (table 3), the critical resources of the conformance layer are ex-
plained.
Resource Description
ValueSet A ValueSet defines a set of coded values (take a look at ”Using Codes”
for more details) that can be used in a particular element.
StructureDefinition A StructureDefinition is what you build when you
build a profile. The StructureDefinition contains rules
about how a resource (or type) and its data elements are
used in a particular context. A structure definition
references value sets for the coded elements in a resource.
CapabilityStatement A CapabilityStatement is a statement of the kinds
of resources and operations provided and/or consumed by a
application. The Capability Statement references profiles
to describe specific use of resources by the application.
ImplementationGuide An ImplementationGuide is a document that is
published by a domain, institution or vendor that describes
how FHIR is adapted to support a certain use case
(or set of use cases). An implementation guide is a
collection of capability statements, profiles, value sets,
and (narrative) documentation describing a set
of interoperable applications.
Table 2: Key resources of the conformance layer [58]
3.1.1. Profiling of resources
The general question of why profiling is done is already answered; to help institutions
and stakeholders to represent their data model correctly. However Simplifier names more
goals [58]:
1. Communicate to humans what is decided or expected
2. Enable automated checking/comparison
3. Support code-generation / runtime discovery
4. Create publishing/exchange eco-system
5. Allow testing conformance
While it is generally possible to work without profiles in FHIR, the solution would be
very inconvenient. FHIR profiles enable to check the syntax of a resource by validat-
ing the constraints added to the profile. In the best case, the application will do this
automatically.
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A difference has to be made between layered profiles and derived profiles. The second ones
are ”profiles on profiles”, meaning constraints are added on an existing profile, whether
the same developer or an external have created it. To understand derived profiles further,
the chapter 3.1.2 explains the hierarchy of profiles and how it helps institutions adjusting
their resources for particular needs.
3.1.2. Hierarchy of Profiles
FHIR profiles are separated in different layers, also called the hierarchy of profiles. In fig-
ure 9, the different level of resources and how compatible those are with the corresponding
profiles are shown.
On a higher level ”[...] the profiles are more generic and have a lower volume, while a
higher volume of resources will conform to these profiles. At a lower level, the profiles will
be more specific and have a higher volume, while there will be fewer resources conforming
to these profiles.” [46]
Figure 9: Hierarchy of profiles in FHIR [46]
Starting with the set of all resources, those naturally cover the most significant amount of
data. According to the rules of profiling, all resource are compatible and valid in the layer
of the ”Core Profiles”. This can be established due to the states (explained in chapter 3.2).
Meaning that all FHIR resources have to be compliant to the profiles HL7 is providing in
the standard.
Going down the levels, the ”National resources” can be validated against the profiles on a
national level, but not necessarily against the core profiles. Giving a concrete example at
this point, not all nations need the same fields and clinical information in their resources.
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Some might need different fields, need to restrict profiles, force them to contain a particular
field, or extend them by details as in this specific example.
The patient base profile of Germany, for example, contains an extension in the form of an
identifier named ”VersichertenID_GKV”. This relegates to the health insurance and the
unique identifier of the patient and is a unique identifier, not included in the FHIR base
profile of the patient (appendix D.1).
The Netherlands, on the other hand, don’t need this precise identifier; however, they
include an extension named ”preferredPharmacy” to refer to the patient’s preferred phar-
macy (appendix D.3).
Both nations have developed their base profile of the patient resource, based on the code
profile, provided by HL7 FHIR (figure 10).
Figure 10: Example of national Profiles in FHIR [42]
Going on with the profiles of the different nations, regions can define their derived profiles
based on a higher layered profile. They can choose to use the national profiles, as well as
the core profiles for some reason.
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When an organization or an institution, like in the concrete use case of this thesis the
University Hospital of Cologne, need more specific information, they can adopt an existing
profile in the hierarchy and adjust their changes to match the internal workflow and stay
interoperable to a certain level on cross-organizational communication.
The different layers of profiles are not limited to the four displayed in figure 9. If for some
reason additional profiles on a separate layer are needed, FHIR doesn’t have any rules
about restricting the number of profiles or layers.
However, the scaling of profiles, down to the organizational level as an example, is limited
up to a certain point. The different techniques and limitations can be found in chapter
3.2.
3.2. Limits and Scope of Profiling
An important aspect when discussing the limits and the scope of profiling is to determine
what can be profiled. As stated in the ProfilingAcademy, profiling usually starts with a
core resource of FHIR, for example, the Patient resource.
A typical example would be, to use the element name or the resource and extend the
minimum cardinality to 1 using a profile. By this process, the name becomes obligatory.
The birthplace, as a second example, can be customized to the maximum cardinality of
0. This would remove that element from the profiled resource.
Giving these examples, it has to be mentioned that the profiling of cardinalities in FHIR
is limited too. A profile can restrict the cardinality, but only within the limits of the
base structure. The following table (table 3) shows what changes of the cardinalities are
allowed and which ones are out of bounds.
derived/base 0..0 0..1 0..n 1..1 1..n
0..1 yes yes no yes no
0..* yes yes yes yes yes
1..1 no no no yes no
1..* no no no yes yes
Table 3: Allowed changes in cardinality using profiling [44]
Besides changing the existing elements, new ones can be added too. As an example, the
hair color of the patient could be relevant. It’s also important to mention that codes and
valueSets can be modified. Talking about the example of the patient resource, the own
”haircolor”-extension could be limited to a particular list of values, or it could refer to a
coding-system like SNOMED CT (explained earlier in this thesis, take a look at chapter
2.1).
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In the following sections, different elements and parts of the profiling-process are explained
further. At this point, not all aspects of profiling can be described in detail. The focus
is therefore set onto building up a general understanding of the different elements and
providing the base for a further understanding of this thesis. The technical aspects and
unique toolings are not explained in detail and cannot be seen as part of the following
description.
3.2.1. Extensions
Up to this point, core resources have been mentioned a few times. Because it would
be hardly possible for FHIR to incorporate all stringent requirements, the specification
is designed to allow the previously mentioned additional implementations; the so-called
extensions. The ProfilingAcademy writes that ”Extensions are a way to extend an element
or resource to include additional elements not present in the original, e.g., adding a
birthplace in addition to the date on the Patient resource.” [59]
For clinical safety, FHIR has included an ”isModifier”-Flag. This is used, when a resource
is changed significantly in its conceptual understanding. In typical cases, the system tries
to process every resource, even if it doesn’t understand a specific extension. The ”isMod-
ifier”-Flag signals the system, that processing without understanding the full context is
not safe.
To use extended resources in the daily workflow and sending them to different systems,
it has to be made sure that the resources are published (for example on Simplifier.net)
Worthy to note at this point is the ”Extension Definition”, which defines an URL to
identify the extension. Further, it describes the context where the extension can be used,
meaning a single extension has to be defined once and can be reused in different profiles.
3.2.2. Slicing
Adding a specific constraint to an element can be to strict, in case that the constraint
shouldn’t apply to the whole element. Slicing is the logical option to create different parts
of an element, named slices, which can contain constraints that are contradictory to each
other.
To help the system identify the different slices, a discriminator is used. It should allow
systems to determine which slices belong to which section. Initially slicing an element, the
discriminator has to be assigned. To do this, the path and the type need to be determined.
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The ProfilingAcademy states that FHIR defines five different types [60]:
value - ”The slices have different values in the nominated element”
exists - ”The slices are differentiated by the presence or absence of the nominated ele-
ment”
pattern - ”The slices have different values in the nominated element, as determined by
testing them against the applicable ElementDefinition.pattern[x]”
type - ”The slices are differentiated by type of the nominated element to a specified
profile”
profile - ”The slices are differentiated by conformance of the nominated element to a
specified profile”
By the time an element is sliced, the creator can decide whether or not he/she wants to
allow additional content added to the different slices. FHIR specifies three different rules,
about how to define this (table 4).
An example, mentioned in the Simplifier Profiling Academy is that the Netherlands have
different ways how to identify practitioners (UZI number, AGB code, BIG code) [46]. In
case that UZI number and AGB code are slices, and the rule is defined ”open”, the BIG
code can be added. When the rule is defined as ”close”, the BIG code cannot be added.
Lastly with the rule allowing ”open at end”, the BIG code can be added, but just at the
end of the identifier-list. [60]
Code Definition
closed No additional content is allowed other than that described by the slices
in this profile.
open Additional content is allowed anywhere in the list.
openAtEnd Additional content is allowed, but only at the end of the list.
Note that using this requires that the slices be ordered,
with makes it hard to share uses.
This should only be done when absolutely required.
Table 4: Rules about the usage of slicing [60]
A small example of HL7 how slicing can look like is visualized. Here, shown in figure 11,
the ”component” element contains a nested code and a value attribute. Profiling a ”Blood
Pressure Profile”, as a common example, the component is sliced into two different slices.
One for ”Systolic” and one for ”Diastolic” pressure. As seen in the picture, the different
values also got different constraints for valueSets in the form of ”CodeableConcepts” to
use.
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Figure 11: Example of the slicing process on the Observation resource [44]
Another example of a sliced resource, in the form of a MedicationStatement in XML-
format, can be found in the appendix (appendix E).
3.2.3. Terminology
Terminology is generally about the codes in the available data. A few different FHIR
resources cover it. Figure 12 is showing those resources and their relations.
The CodeSystem is defining a set of concepts. These codes can be used to describe the
inventory and values of specific clinical content. Further, the ValueSet defines a selection
of codes to be used in particular content. Concerning the CodeSystem, the ValueSet
selects codes from one or more different sources.
Different data types can describe the data of CodeSystems in Coded Data Types.
1. Code - The list of codes is fixed. A common example is the gender
2. Coding - ”contains elements to capture the system, its version, the value of the
code itself and a textual representation” [46]
3. CodeableConcept - Contains 1-n Codings, as well as an optional textual repre-
sentation
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Figure 12: Concept map of terminologies in FHIR [46]
When used in profiling, the ”CodeableConcept” is usually the safest choice, since it in-
cludes the Coding which enables the profile to be reusable.
Lastly, the ”Elemental Definition” defines a particular element in a resource or an ex-
tension. Taken the name of a patient as an example, it has different properties like the
cardinality or the data type. The elemental definition is further defining the data type
and the ValueSet for the individual element.
The Terminology, in the context of profiling, refers mainly to the ValueSet and the Cod-
ingSystem resources. What should be known about terminology is, that a field has a
”strength of the binding” to a particular ValueSet.
Binding strength Meaning How you can profile this
Required You can only select codes You can remove codes from
from this valueset and no other the valueset but you
cannot add any new codes
Extensible You must select code from this You can add and remove codes
valueset, but you can use other from the valueset but don’t
codes if the valueset doesn’t duplicate or replace
have a matching code existing ones
Preferred You should select codes from You don’t have to use
the valueset, but it’s not these codes, but it’s
strictly necessary recommended that you do
Example This is just an example of codes You should set this to
you could use a valueset of your own
or at least strengthen
the binding
Table 5: Strength of the binding in ValueSets [46]
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3.2.4. Profiling Tools
FHIR has several tools available to help developers and consultants while creating and
customizing profiles. Besides the basics of building and designing a profile, it can also come
into the discussion, if a profile about an individual use case has already been designed.
Several public pages are a good start to search for potential public profiles, these include,
but are not limited to:
1. FHIR Registry7 ”[...] is a central point to search for published FHIR Resources:
profiles, extensions, terminology-related and all others created for FHIR STU3 in
International, National, Institute or Regional projects on simplifier.net” [61]
2. Simplifier8 ”[...] is a FHIR registry. You can find FHIR profiles, view and learn
about them and other FHIR conformance resources, like extensions, valuesets, and
more. Simplifier is the ideal place to learn about the relationship between different
profiles.” [62]
3. FHIR Extensibility registry9 is the official registry by HL7. Just like the other
options, this registry contains a collection of customized ”StructureDefinitions”. It
is particularly referencing towards http://hl7.org/fhir/registry as another registry.
The philosophy of FHIR is to be public and free-of-charge. To support this and the
common sense of interoperability, it is crucial to keep profiles as close and conform to
national and regional profiles as possible. So when profiles are published, they can be
used by other companies and stakeholders without much effort.
To support this, personal solutions and ideas should be published for the community to
find and extend them for personal and collaboration needs.
To help developers understanding profiles and make working with them easier, some
naming conventions are to be followed. According to the Simplifier Profiling Academy
[63], those rules include:
1. UpperCamelCase for resources
2. lowerCamelCase for elements and slices (chapter 3.2.2
3. lowercase for extensions, using the following format: [context]-[name]
4. Consider to include the resource type of the customized resource in the name of
your profile
7https://registry.fhir.org
8https://simplifier.net
9http://hl7.org/fhir/STU3/
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The narrative in FHIR represents a textual description of what the resource/profile is
used for. To support this, a short description of the usage, or at least if it is an extension
or a profile, should be included.
Different projects, however, can have a different scope. Depending on that, a different
attempt at profiling can be used. The two approaches to be discussed is the close and
the open modeling. On the one hand, an open model is generally more generic, due to
a lower amount of constraints defined. Regional projects are advised to use this model
because it enables generally higher flexibility for downstream projects. Due to the more
generic kind of modeling, the profiles can be reused easier and with less effort.
The closed modeling approach limits the profile by adding more constraints and reducing
the possible data the profile can contain to the minimum necessary.
Figure 13: Profiling using the closed model approach [63]
Downstream projects should mostly go the way of making a closed modeling approach.
This way the required data can be easily circumscribed. These profiles are modeled by
constraining the maximum cardinality of unused fields to 0. This can be done by slicing
the elements (chapter 3.2.2) and setting constraints on the slide, limiting the cardinality.
A huge benefit of the closed modeling is that application with a graphical user interface
can represent the received data without having to use custom filters to reduce the data
displayed to the relevant fields.
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Figure 14: Profiling using the open model approach [63]
Designing a profile according to the open modeling approach doesn’t limit the cardinality,
allowing the end-user to fill in the necessary data, even though it is not explicitly used to
the defined use case.
Though this approach is increasing the amount of data that needs to be covered, some
of the information transferred might not be processed by the application and are filtered
out.
Still, creating a derived profile of an open modeling approach leaves the designer with more
possibilities to scope the profile to their personal needs. Customizing a closed modeling
approach, like shown in figure 13, the developer is not able to re-enable for example the
”notDone”-attribute, since the cardinality was set to 0..0 before (for possible cardinalities,
take a look at chapter 3.2).
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The following table shows the pros and cons of both different modeling techniques.
Open modeling Closed modeling
Pros Forward compatibility No need to support all elements
Focus on what must be supported More specific models
More generic data fit Smaller, straightforward models
More implementer feedback
Cons More elements have to be supported More versions of models
Larger, vaguer models Only backwards compatibility
Less implementer feedback New elements require new version
Table 6: Advantages and disadvantages of different modeling (adapted from [46])
The table doesn’t claim to be entirely exhaustive but to name the most important aspects.
Different projects have to choose individually if open or closed modeling is a better choice
for their specific use case.
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4. Clinical Studies
Clinical investigations always start with the development of clinical protocols. The proto-
col, in the form of a document, describes how clinical trials will be conducted - including
objective(s), design, methodology, statistical considerations and the organization of the
trial. It also ensures measures to safeguard the safety of the participants and the integrity
of the collected data.
4.1. Setup of a Clinical Trial
The information on the general setup of a clinical trial is generally also found at high-level
synopses of the trial.
Figure 15: example of a study on clinicaltrials.gov [64]
The public webpage ”clinicaltrials.gov” provides the opportunity to view different public
trials and get to know the various aspects further. Central aspects of conducting clinical
trials are:
• Objectives/Purpose
• Study Design
• Selection and Exclusion of Subjects
A distinction has to made between clinical trials and observational studies. In the follow-
ing work, clinical trials are set into focus.
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4.2. Clinical Trial Protocol
A research protocol describes the background, rationale, objectives, design, methodology,
statistical considerations, and organization of a clinical research project. Besides the main
setup of items listed above, a protocol should include the following topics (based on ICH
Good Clinical Practice guidelines) [65]:
• Treatment of Subjects
• Assessment of Efficacy
• Assessment of Safety
• Adverse Events
• Rules for deciding when to discontinue the Study
• Statistics
• Quality Control and Assurance
• Ethics
• Data handling
• Project Timetable/Flowchart
• References
• Supplements/Appendices
The most complex aspects of this list are the ”Treatment of Subjects”, ”Assessment
of Efficacy” and ”Assessment of Safety”. They entail describing procedures, which are
scheduled in so-called ”visits”. They have to be performed in a very rigid timeframe.
We will here focus on two different and equally important aspects. The first is the ”Sched-
ule of Activites” (chapter 4.2.1) and second is the ”Dosing and Administration” (chapter
4.2.2).
4.2.1. Schedule of Activities
The procedures to be accomplished at each study visit have to be captured by the schedule
of activities. This also includes, among other aspects, any tests for eligibility, participant
randomization or stratification and decisions on study intervention discontinuation. Dif-
ferent procedures, contributing to the participant’s eligibility, should be annotated to
distinguish between other routine procedures. Study objectives and endpoints need to be
annotated too.
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Procedures which are not directly related to the trial need to be captured sparingly and
with consideration, as they can possibly add unnecessary complexity and distract from
recruitment.
To determine the appropriate windows - which should be stated for all visits - considering
the feasibility and relevance of the visit time points to study endpoints is essential.
4.2.2. Dosing and Administration
This description stipulates the procedures for selecting a participant’s dose of study in-
tervention and control product. With a focus on drugs, that includes the duration (e.g.,
the length of time) as well as the timing of the doses (e.g., time of day and interval).
Also, the planned route of administration (e.g., oral or intravenous) must be taken into
account.
In the protocol, this part states the starting dose and schedule during the study interven-
tion and control product. It also includes the maximum and minimum duration for the
participants who continue to stay in the study.
The protocol will, if applicable, describe the dose escalation schema and dose regimen. It
will further state any minimum period required before a participants dose might be raised
to a higher dose or dose range.
For this to be applicable, the protocol should further state the conditions necessary to
change the particular doses of a patient. In particular with regard to toxic or other
warning indicators.
It will address dose modifications, especially for specific abnormal laboratory values of
concern or other adverse events (AEs), which are known to be associated with the planned
study intervention.
The protocol must provide criteria, used to determine dose escalations. It also has to
state the dose-limiting effects, which are anticipated, explicitly.
Positive responses to the intervention by participants have to be mentioned in the protocol
too. It needs to specify whether study intervention administration would progress to
still higher doses. If appropriate, provide a dose de-escalation schema with intervention
modifications.
Specific instructions to participants of the study, about when or how to prepare and take
the dose(s) need to be described. It has to include, how delayed or missed doses should be
handled. Specific instructions and safety precautions for the administration of the study
intervention have to be included too.
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5. Approach of mapping FHIR Profiles to Research
Protocols
In 2015, Hugo Leroux, Alejandro Metke-Jimenez, and Michael John Lawley approached
building a mapping between CDISC ODM and FHIR [66]. While this approach is neither
entirely obsolete, or the only possible solution of mapping the data, it provides an overview
of how a reasonable mapping approach could have looked like.
Figure 16: Approach for mapping CDISC ODM Resources to FHIR [66]
Since this model was created back in 2015, some of the resources can be mapped to a
better and more efficient way nowadays. Also, the shown model is not comprehensive in
the way it is representing resources. FHIR generally offers the ”ResearchStudy” resource,
which has the maturity level 0. This means that the resource was published in the
current release. The following approach is, therefore, trying to build an initial mapping of
clinical trials, especially the clinical protocols, based around the ”ResearchStudy” resource
(chapter 5.1.1).
In general, this chapter discusses a more up to date approach for mapping FHIR resources
to research protocols. Due to the limited time of this thesis and the complexity of the
data, not the whole process of storing clinical trial protocols can be discussed.
5.1. Representing Clinical Trials as FHIR Resources
In the following subchapters, the detailed approach of representing clinical trials as FHIR
resources is discussed. We start with an analysis of the different resources FHIR is pro-
viding to represent the study. We chain the resources together as much as possible to
build a coherent construct.
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We follow with a profiling solution of the problem and an analysis about how the answer
can be integrated into existing resources, as well as a proof of concept by creating a
resource chain of the most essential resources.
5.1.1. General representation of Clinical Studies in FHIR Profiles
FHIR does support the concept of clinical trials in the latest release10 by using the re-
source ”ResearchStudy” (figure 17). HL7 defines the scope and usage with ”[...]developing
RCRIM11 standards to improve or enhance information management during clinical re-
search and regulatory evaluation of the safety, efficacy, and quality of therapeutic products
and procedures worldwide.” [67]
Figure 17: ResourceStudy Resource [67]
Besides some general information, such as the title of the study or the current status,
FHIR also provides the field ”arm” to support multi-armed studies (information about
multi-armed studies are found in chapter 2.3.1) The ”protocol” field allows a reference to
a ”PlanDefinition” resource. Standing at the maturity level 2 means, that the resource
has already been exchanged ”between at least three independently developed systems
leveraging at least 80% of the core data elements” [68]
10The currently latest release of FHIR is STU3, released at the 19th April 2017
11Regulated Clinical Research Information Management
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As to the ”PlanDefinition” resource, it can be described as a pre-defined set of actions,
however still be flexible to represent a vast area of workflows. ”PlanDefinitions” can
contain a list of actionDefinitions, where particular actions describe activities to be per-
formed.
Figure 18 shows the reference relationship between ”PlanDefinition” and ”ActivityDefi-
nition” resources.
Figure 18: Relationship between PlanDefinition and ActivityDefinition [69]
For this approach the relevant fields in the ”PlanDefinition” resource are ”action” with
a cardinality of 0..* (from 0 to many) and the subfield ”definition” with a cardinality of
0..1 (exactly 0 or 1 time). These fields are shown in figure 19 and figure 20.
Figure 19: ActionDefinition in the PlanDefinition resource [69]
An action is a ”BackboneElement”, meaning it is defined as part of a resource definition (in
this case ”PlanDefinition”). In general ”BackboneElements” can be described as elements
which are only internally available inside a resource. With the knowledge of a software
engineer, these are comparable to anonymous classes in object-oriented programming.
According to the definition of the standard, Data Type elements are not using it generally.
[70]
As mentioned before, the focus is mainly set into the definition (shown in figure 20),
which is, if stated, a reference onto an ”ActivityDefinition” or another ”PlanDefinition”
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resource.
Figure 20: ActivityDefinition in the ActionDefinition of the PlanDefinition resource [69]
As the name indicates, the ”ActivityDefinition” describes an activity to be performed.
HL7 states that the ”ActionDefinition” itself doesn’t indicate the actual intent to carry
out a particular action but can be seen more like a reusable template used to construct
specific request resources like ”ProcedureRequest”12 or ”MedicationRequest”13.
Figure 21: Reference to Medication in the ActivityDefinition resource [71]
As shown in figure 21, the ”ActivityDefinition” resource, however, contains the field ”prod-
uct[x]” which has the subfield ”productReference”. Through this, ”Medication” and ”Sub-
stance” resources can be referenced.
Though this List of resources is not exhaustive, it provides an idea of how FHIR handles
the representation of a clinical trial so far. Summarized, the reference flow of the resources
from the definition of the study to the medication can therefore be described as:
ResourceStudy→ PlanDefinition→ ActionDefinition→ ActivityDefinition→ Medication
Important to note at this point is, that cardinalities of ”ResourceStudy” to ”PlanDefini-
tion” and from ”PlanDefinition” to ”ActionDefinition” are 0..*, meaning it doesn’t have
to appear but can also be instantiated multiple times. The references to ActivityDefini-
tion and Medication are also optional, but with a cardinality of 0..1, meaning they can
appear one time at maximum.
12https://www.hl7.org/fhir/procedurerequest.html
13https://www.hl7.org/fhir/medicationrequest.html
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5.1.2. Problems about the current representation
Even though the resources and references FHIR provides already cover a vast area of the
aspects needed for clinical trials, not every use case can be easily depicted; without some
adjustments at least.
The logical approach for planning a clinical trial would be, the ”ResearchStudy” resource
providing the general representation. It can refer to ”PlanDefinitions”, which can themself
relate to multiple ”ActivityDefinitions”.
There are several issues to point out here: The ”Medication”, related in an ”Activity-
Definition” doesn’t represent a real dose of medication for a patient to take, but only a
representation of the drug itself.
While ”ActivityDefinition” (figure 21) can describe the doses of medication on an abstract
level, as is needed for the planning clinical trials, a representation of the substances
(medication), as well as logging - whether the drug was taken - is needed on the level of
an individual patient.
The ”MedicationRequest” resource (figure 22) is able to visualize the medication to be
taken by a specific patient.
Figure 22: Representation of the MedicationRequest resource [72]
As shown in the picture, the field ”MedicationRequest.definition” allows a reference to an
”ActivityDefinition”. Contextually this describes the process of conducting a particular
record out of the abstract template for an individual patient.
Since the particular scenario requires a concrete ”Medication” as well as a subject to re-
ceive the medication, both are referenced in ”MedicationRequest.medication[x]”, allowing
a reference to a ”Medication”, and ”MedicationRequest.subject” respectively. ”Medica-
tionRequest.subject” in turn references towards a ”Patient” or a ”Group”.
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Based on the request, figure 23 shows the state of affairs of the patient. It can be compared
with a nominal vs. actual comparison - i.e., planned vs. given dose.
The ”MedicationStatement” resource is, for example, stating elements like the date where
the statement was asserted and must have the declaration included as to whether the
patient has taken the drug. It also contains multiple references, which are necessary to
close the chain of the resources used by a study and fit into its place correctly.
On the one hand, ”MedicationStatement.basedOn” can refer to one of the previously
discussed ”MedicationRequests”, allowing to compare between the planned medication of
the particular patient and the taken doses.
The field ”MedicationStatment.context” on the other hand is referencing towards an ”En-
counter” or an ”EpisodeOfCare”, describing the visit.
Figure 23: Representation of the MedicationStatment resource [73]
In this concrete topic, the ”Encounter” is the resource of interest.
An ”Encounter” in FHIR can be used to represent a visit to the patient. A major issue
here, however, is that it is currently hardly possible in FHIR to reference from a ”Re-
searchStudy” to ”Encounter” or vice versa. As study visits, however, are a fundamental
concept, the common sense of needing this reference is obvious. The chain of resources,
representing the clinical trials, have to be enlarged by a reference towards ”Encounters”.
If this reference would be available, possible Chains would be:
1) ResourceStudy→ PlanDefinition→ ActionDefinition→ ActivityDefinition
2) ResourceStudy→ Encounter→ MedicationRequest
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3) ResourceStudy→ Encounter→ MedicationStatement
With these possible concatenations of resources, the study medication of patients, as
well as the doses can be modeled. Also, the regular study visits can be represented in the
different ”Encounter” resources, providing general information about the individual status
of a patient during the study, as well concrete information about the specific medication
for the patient through the ”MedicationRequest” and ”MedicationStatement” resources.
Focusing now on ”Encounter”, different elements such as the status, the type, a subject,
and participants can be depicted. What is striking about this resource is, that is doesn’t
support a link towards any of the previously mentioned elements in the resource chain.
However, as shown in the example chains before, ”Encounter” is not necessarily the last
element inside the chain.
We now move on to the mentioned resources relevant for the clinical trial. Patients,
Practitioner, and others can be linked out of ”Encounter” but are not taken into closer
view at this point.
Figure 24: Representation of the Encounter resource [74]
Comparing all previously mentioned resources, especially the ”ResearchStudy” (figure 17)
as well as the ”Encounter” resource (figure 24), no reference connecting ”Encounter” with
the existing resource chain can be recognized.
To follow the goal of obtaining the possibility to represent study visits in the wanted form,
creating this reference is taken into closer consideration in the following chapter.
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5.1.3. Customization to achieve structured Study Representation
With the problem statement laid out in the previous section (chapter 5.1.2), we set out
to define a solution approach. It seemingly will require the construction of a reference
between ”ResearchStudy” and ”Encounter”.
However, before we elaborate on this solution a certain aspect of FHIR has to be pointed
out. Since FHIR is an international and relatively detailed standard, modeling extensions
can’t be done right away. It’s essential to discuss proposed changes, for example in the
form of extensions, with the FHIR community to provide a common knowledge and ensure
not to make changes at unfavorable resources for the specific use case.
The best focal point for a useful discussion is the official FHIR chat14. All kind of devel-
opers, manager, and people working with FHIR are exchanging about different aspects
and topics on this platform.
This concrete solution of planning an extension of FHIR by building a reference from
”ResearchStudy” towards ”Extension” was proposed in that forum and it turned out to
be the wrong approach. This can be explained by having a look at the ”ResearchStudy”
and its purpose.
As mentioned previously, the current resource chain builds an abstract model of the study
focusing on the study itself an not on the patient. Taking a closer look at the resources,
none have any direct references towards a particular patient, keeping them on a highly
abstract and theoretical level.
However, focusing on ”Encounter”, it refers towards a concrete patient and describing
particular circumstances. By referencing from ”ResearchStudy” towards ”Encounter”,
the abstract level of the clinical trial would be violated.
Figure 25 is, therefore, to be taken as a wrong approach, since this representation of the
”ResearchStudy” resource is doing precisely what was mentioned before; breaking through
the abstract level by adding concrete, patient-related, information.
14The official FHIR chat in the form of a Zulip-platform is reachable on https://chat.fhir.org
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Figure 25: Semantical bad example of an extension
A semantically better way of creating an extension is, to create a link from the specification
(in this case ”Encounter”) towards the abstract level of resources. This is a definite
example of how quickly mistakes can be made if not all possible solutions are explored
sufficiently.
Once a semantically correct solution approach has been found, we use the Forge tool to
be sure to develop a syntactically correct external extension which is valid for integrating
later on into resources.
Figure 26: Creating an extension in Forge
The figure 26 shows the creation of an extension with the help of firely’s tool Forge.
Even though the extension could also be created with plain JSON or XML, the graphical
user interface supports the developer, for example with a syntax check while building the
extension. The essential parts of the extension as an XML-File, as well as the extension-
table, can be found in the appendix (appendix F).
The results of creating the extension with Forge are shown in figure 27. It is illustrating
a reference to the ”ResearchStudy” resource, just as planned.
The field ”url” is a fixed value, pointing towards the online location of the extension. It is
always necessary for an extension to have this field (therefore Forge is adding it automat-
ically) to enable an application to download the extension to process it automatically.
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Figure 27: Extension representing a reference towards the ResearchStudy resource
Since having this extension alone doesn’t enable the ”Encounter” resource to refer to
the clinical trial, a profile has to be created. Figure 28 shows the integration of the
”Extension” into the ”Encounter” resource.
Important to notice is that an open modeling approach has been selected to enable a
natural use of ”Encounter”. Only when a particular reference is needed, it can be added
towards the ”Encounter.basedOn” attribute.
Figure 28: A profil of the Encounter resource, enhanced by an Extension
Concluding, using this profile, a reference from visits towards clinical trials is made pos-
sible. Furthermore, the resource can generally be used, no matter if a reference towards
the ”ResearchStudy” is provided or not.
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Assumed the reference is made, it is possible to request all ”Encounters” of an active
study, even though no reference from the trial towards the visits is given. This can be
achieved via the FHIR search framework and the so-called, reverse chaining concept of
FHIR. Since it’s no actual topic inside this thesis, the concept isn’t explained further15.
5.1.4. Proof of Concept
After discussing the representation of clinical trials in FHIR and pointing out current
problems, the following subchapter deals with the proof of concept of the reference chain,
as well as the extension added to the ”Encounter” resource.
Establishing a situation to test the resources FHIR is providing, a real clinical study which
Systems R&D are providing infrastructure for, is taken as a use case to build resources.
We specifically take the CLL2-BAG study (part of it depicted in figure 29).
Figure 29: Example extract of the CLL2-BAG study [64]
In order to keep the resources compact, not all possible data of the rather big complex
study is shown. The focus is set on proving the possible references between the different
focus points instead.
Clinical trials generally separate into different epochs - which are high-level time phases
in a trial, and cycles which refer through the medication phases of the trial. Usually, visits
are laid out along the individual phases. Figure 30 shows a different kind of data for each
phase. Besides the medication, we have tests to confirm the effect and events which are
15Further Information about searching in FHIR and reverse chaining can be found here:
https://www.hl7.org/fhir/http.html#search
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observed in detail in order to detect any adverse effects. We also note that concomitant
medication is also documented in order to infer any unreported side effects which are
trying to be managed by the physician and could be caused by the investigational drug.
Taking the investigational medication as an example, the ”GA101” antibody is given at
day 1, day 2 and day 8 of the study, according to the doses displayed in the picture.
The second medication of interest in this scenario is the ”ABT-199” - also a monoclonal
antibody.
Those two medications and the doses were taken as the example to include into different
”ActivityDefinitions” (appendix G.3).
Figure 30: Clinical Details for Cycle 1 of the CLL2-BAG
However, starting to create a study is typically done by building a ”ResearchStudy”
resource (appendix G.1). In this case, the study was assigned the id ”researchstudy-
soa-1”. Different fields of the resource are referencing onto the trial definition on the
”clinicalsite.org” trial management system.
The trial start date was set to the 6th May 2015, starting with the recruitment of par-
ticipants. Sponsor and participalInvestigator are relating to the University Hospital of
Cologne and Dr. med. Paula Cramer as principal investigator.
Moving down the chain, a reference towards the study protocol is made inside the ”Re-
searchStudy.protocol” field. This reference is set towards the ”PlanDefintion” with the
id ”plandef-soa-1” (appendix G.2).
Starting by providing general information, such as the version of the protocol, the name,
and the status; the study protocol resource has the flag ”experimental” set to true. This
indicates that it is just for testing purposes and cannot be used for a real trial. Beside
some other general information, the ”PlanDefinition.action” is mainly set into focus. For
this proof of concept, two different actions have been defined, both referencing straight
onto previously mentioned activities (appendix G.3).
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Since the ”ActivityDefinition” resource can be used to create a generic concept of med-
ications and doses during the study: ”GA101” and ”ABT-199” (shown in figure 30) are
defined with some sample doses in these resources. The timing and the quantity, just as
the repeating events for ”ABT-199”, are listed as examples and not in every detail.
Next up in the resource chain is the ”Medication” (appendix G.4). The essential data
to mention here is the code and the form, both of which refer to the coding system
SNOMEDCT. Otherwise, these resources have the required id and a status, setting them
both to ”active”.
Working together closely with the medicine definition itself is the ”MedicationStatement”
G.7) and the ”MedicationRequest” (appendix G.6). Starting with the statement, the
”MedicationStatementbasedOn”-attribute refers to a ”MedicationRequest”, and the con-
text is defining the ”Encounter” in which the medication was asserted.
We should also mention the apparent reference towards the medication and the patient
to receive their doses, as well as the reference to the treatment itself. Note that this
resource always needs the ”taken”-attribute to show whether the patient has taken the
investigational substance.
When talking about the ”MedicationRequest”, many things are similar to the ”Medica-
tionStatement”. However, the request doesn’t contain a date where taking the substance
was asserted but a period, visualizing the timestamp when the request for medication was
authored. Other then the ’taken’ attribute, this resource is carrying an ’intent’ and can
refer to a requester of the medication.
Last but not least, the customized resource ”Encounter” was filled with some sample data
such as a status, a class, a subject, and a participant.
Most importantly, the ”extension” attribute has an ”url” pointing to the particular ex-
tension. In this specific case, it is the private simplifier project of the author and the
creator of the extension. The ”reference value” is pointing towards the clinical study -
”researchstudy-soa-1” - also displaying the name.
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5.2. Software Approaches and Improvements
Taking into consideration that machine-parsable data, in the form of FHIR resources, is
raised during the study, it opens up way more possibilities for software-based assistance.
FHIR applications are commonly evolving and given the fact that clinical trials at the
Medical Systems R&D group are already using software solutions planning their studies,
it should be possible to improve these systems by adding and adjusting functionality.
Developing a solution onto an FHIR backend can be the same as building upon a classical
data warehouse structure for example. The process of development won’t change very
much. A positive feature, however, is that FHIR is also not going to exacerbate the
process further. [75]
The significant changes in developing an application with an FHIR backend aren’t coming
from the choice of programming languages but when the application starts working with
data. Since FHIR has a far and in-depth developed data model, no custom data structures
have to be conceptualized and designed. If some of the data doesn’t fit into the open data
model, the answer in FHIR is to create profiles to alter the resources to accommodate
with the data.
Talking about a concrete example, the idea of creating an automatic comparison between
the medication planned for the study (defined in the ”ActivityDefinition”), the medication
for the particular patient (depicted in the ”MedicationRequest”) and the medication actu-
ally taken by the patient (logged through the usage of a ”MedicationStatement” resource)
is definitely a step into the right direction.
Such systems would not only be able to communicate and exchange data efficiently, thanks
to the interoperability of FHIR resource, but also enrich the medical assistance of the
patients because the data could be available for the responsible practitioners way faster.
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6. Conclusion
The project of mapping clinical trials and protocols to FHIR resources is still in progress
and will go on after the work on this thesis is finished.
So far, the concept of profiling in FHIR is a well-defined process. Concepts of clinical
studies in FHIR, however, are quite new and for such a complex topic the amount of
information that needs to be modeled and mapped isn’t trivial.
Though FHIR is continually improving concepts in respect of clinical trials, at closer
look at the maturity levels of the resources used, it’s evident that the resources are still
improving. The HL7 organization has stated that the standard is going to expand further
for trials and their documentation on the next release of FHIR. Since the 2015 publication,
a lot has changed and one of the achievements of the project was to gain an overview of
FHIR’s resources for a mapping proposal. My personal understanding of FHIR itself and
clinical trials is one of the most significant achievements. A first approach of profiling the
resources to the needs of Clinical Trials has been achieved.
What follows is a personal conclusion derived in the form of a lessons learned during the
project. This opinion does not claim to be impartial.
It also seems fitting to give a future outlook of where to move on beyond the project in
order to achieve a full representation of clinical trials in the form of FHIR resources.
Also, new developments in FHIR offer exciting new possibilities in the way clinical trials
could be conducted in the future - specifically with regards to extracting source data
relevant for research from primary systems (e.g., EMR).
6.1. Lessons learned and Results
At the end of this thesis one should sum up the main issues encountered and solution
approaches which were developed. In general, I would note that the conceptual model of
clinical trials has not yet matured sufficiently in FHIR but that given the right approaches,
these can be discussed and reviewed at a surprising pace so as to make their way into the
standard relatively quickly.
Regarding the maturity of the present model, for instance, modifying planned medication
schedules for trials subjects is still very cumbersome to model. In this concrete case,
the ”CarePlan” resource can be considered as a representation of the abstract plan or
schedule.
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However, presently – even following a long discussion on chat.fhir.org – it is not possible
to assign that schedule to a concrete study subject with the existing resources. Even for
such a basic concept, one has to write a custom extension.
In this case, you could potentially establish a relationship between schedule and subject
via reverse chaining. However, the approach would not be feasible in practice since with
several existing CarePlans there is no means of defining ‚the authoritive’ plan for the
study subject.
The specific issue of referencing from visits in a trial, in the form of the „encounter“
resource is an excellent example of how the standard can evolve given the right approach
suggestions: The extension developed for this project was seen as a clear necessity and
was quickly proposed to be adopted in coming releases.
6.2. Future Outlook
So far, only a very narrow domain in search of a solution approach of mapping the
clinical trial to resources could be covered. However, the ”visit” and ”schedule” concepts
are fundamental for clinical trials and a machine-readable format for these concepts is of
great value.
The research on the current representation of clinical trials in FHIR resources has shown,
that HL7 and FHIR are still continually evolving their resources, pushing them to higher
maturity levels and react to the needs of the clinical institutions. One has to state that
the speed at which this work is evolving is very promising compared to previous standards
- such as CDISC PRM, supposedly dedicated to clinical trials, which in 10 years did not
deliver any significant value towards a machine-readable clinical trial protocol.
The general framework of FHIR itself is evolving and making itself extremely valuable
for clinical research. A recent article by Grahame Grieve suggests using Questionnaires
in FHIR not only as a form template but as a query template which can search the
appropriate FHIR resources and pass on the values back and populate any identified
values automatically from source systems (appendix H). This sounds like science fiction,
but in fact, the concept and experimental tooling building on top of FHIR path will be
balloted during this years’ Hl7 meeting in Baltimore in November.
The value of this framework for - say identifying participants for a clinical trial or retrieving
source data to the research database is a quantum leap in converging health care and
clinical research. [76]
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A. Appendix: RESTful API
A.1. Create a Resource
Starting with creating an example resource of a Patient by sending a POST request to
the FHIR-Server.
Listing 1: Create a resource
POST [ base ] / Pat i en t
{
” resourceType ” : ” Pat i en t ” ,
” t ex t ” : {
” s t a t u s ” : ” t e s t i n g pa t i e n t ” ,
” d iv ” : ”<div >.. . </ div>”
} ,
” a c t i v e ” : true ,
”name ” : [
{
” use ” : ” o f f i c i a l ” ,
” f ami l y ” : ”Doe ” ,
” g iven ” : [
”John ” ,
”Sam”
]
}
] ,
”managingOrganizat ion ” : {
” r e f e r e n c e ” : ” Organ i za t i on /1”
}
}
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A.2. Read a Resource
Reading the Patient with the id 1, using the HTTP-GET request to the FHIR-Server.
The second call is also reading the patient, but with requesting JSON as the particular
format of the data.
Listing 2: Read a Resource
GET [ base ] / Pat i en t /1
GET [ base ] / Pat i en t /1?_format=j s on
A.3. Delete a Resource
Deleting the Patient resource with the logical_id ”1”.
Listing 3: Delete a resource
DELETE [ base ] / Pat i en t /1
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A.4. Update a Resource
Updating an existing Patient resource by sending a HTTP-PUT request to the FHIR
Server. The Patient is sent fully and with some exchanged data.
Listing 4: Update a resource
PUT [ base ] / Pat i en t /1
{
” resourceType ” : ” Pat i en t ” ,
” id ” : ” example ” ,
” t ex t ” : {
” s t a t u s ” : ” changed t e s t i n g pa t i e n t ” ,
” d iv ” : ” . . . ”
} ,
” a c t i v e ” : f a l s e ,
”name ” : [ {
” use ” : ” o f f i c i a l ” ,
” f ami l y ” : ”Doe ” ,
” g iven ” : [
”John ” ,
”Sam”
] }
] ,
” b i r thDate ” : ”1991 -01 -27” ,
”managingOrganizat ion ” : {
” r e f e r e n c e ” : ” Organ i za t i on /1”
}
}
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B. Appendix: Conformance Statement
The beginning of the Conformance Statement contains information about the publisher
and metadata about the server. The Conformance Statement is taken from firely, by
requesting it using http://vonk.fire.ly/metadata.
Listing 5: Conformance Statement
<Capab i l i tyStatement xmlns=”http : // h l7 . org / f h i r ”>
<id va lue=”a4155e86 - dfb8 -42 b4 - b5dd - d37c771667d6 ” />
<meta>
<ve r s i o n I d va lue=”3e62ad30 -84 c9 -4 e8a - a fea
-167694875901” />
<lastUpdated va lue =”2018 -07 -21T21 : 29 : 0 1 . 5 07+00 : 00” />
</meta>
<language va lue=”en -US” />
<u r l va lue=”metadata ” />
<ve r s i o n va lue =”0.1” />
<name va lue=”Vonk beta conformance ” />
<s t a t u s va lue=”a c t i v e ” />
<exper imenta l va lue=”t rue ” />
<date va lue =”2018 -07 -21T21 : 29 : 0 1 . 5 07+00 : 00” />
<pub l i s h e r va lue=”F i r e l y ” />
<contact>
<name va lue=”Licensed to ” />
<telecom>
<system va lue=”emai l ” />
<va lue va lue=”vonk@f i re . l y ” />
<use va lue=”work” />
</telecom>
</contact>
[ . . . ]
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C. Appendix: Approval of Clinical Trials
C.1. Approval Process for Drugs and Biologics
Figure 31: Approval process for drugs and biologics [47]
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C.2. Approval Process for Devices
Figure 32: Approval process for devices [47]
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D. Appendix: Example Profiles
D.1. DE-Baseprofile Patient
Figure 33: DE-Baseprofile Patient [77]
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D.2. DE-Baseprofile Patient - JSON
The profile was cut, due to the amount of information and the length of the data16.
Listing 6: DE-Baseprofile Patient
{
” resourceType ” : ” S t r u c t u r eD e f i n i t i o n ” ,
”meta ” : {
” lastUpdated ” : ”2017 -12 -05T18 : 56 : 5 1 . 6 86+01 : 00”
} ,
” u r l ” : ” http : // f h i r . de/ S t r u c t u r eD e f i n i t i o n / pat i en t - de -
b a s i s / 0 . 2 ” ,
” v e r s i o n ” : ” 0 . 2 -WORK” ,
”name ” : ” pat i en t - de - ba s i s - 0 . 2 ” ,
” t i t l e ” : ” Pat ient , deut s che s B a s i s p r o f i l ( Vers ion 0 . 2 )
” ,
” s t a t u s ” : ” d r a f t ” ,
” date ” : ”2018 -06 -18” ,
” pub l i s h e r ” : ”HL7 Deutschland e .V. ( Techn i sches Komitee
FHIR) ” ,
” contac t ” : [
[ . . . ]
] ,
” d e s c r i p t i o n ” : ” B a s i s p r o f i l f ü r d i e Verwendung der
Pat i en t Ressource in Deutschland ” ,
” copy r i gh t ” : ”HL7 Deutschland e .V. ” ,
” f h i rV e r s i o n ” : ” 3 . 0 . 1 ” ,
”mapping ” : [
{
” i d e n t i t y ” : ”KVDT” ,
”name ” : ”KVDT Mapping”
} ,
[ . . . ]
16The full profile can be viewed at https://simplifier.net/BasisprofilDE/patient-de-basis-0.2/~json
62
D.3. NL-Baseprofile Patient
Figure 34: NL-Baseprofile Patient [78]
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D.4. NL-Baseprofile Patient - JSON
The profile was cut, due to the amount of information and the length of the data17.
Listing 7: NL-Baseprofile Patient
{
” resourceType ” : ” S t r u c t u r eD e f i n i t i o n ” ,
” id ” : ” nl - core - p a t i e n t ” ,
”meta ” : {
” v e r s i o n I d ” : ” 1 5 ” ,
” lastUpdated ” : ”2017 -01 -23T13 : 46 : 4 9 . 5 91+00 : 00”
} ,
” u r l ” : ” http : // f h i r . n l / f h i r / S t r u c t u r eD e f i n i t i o n /nl - core
- p a t i e n t ” ,
” v e r s i o n ” : ” 1 . 0 ” ,
”name ” : ” nl - core - p a t i e n t ” ,
” t i t l e ” : ” nl - core - p a t i e n t ” ,
” s t a t u s ” : ” r e t i r e d ” ,
” pub l i s h e r ” : ”HL7 Nether lands ” ,
” contac t ” : [ . . . ] ,
” d e s c r i p t i o n ” : ”A Pat i en t r e s ou r c e as d e f i n ed by the
Dutch Health and Care In fo rmat ion models or HCIM (
Dutch : Zorg in fo rmat i ebouwsteen or ZIB ) Pat ient , with
add i t i o n s from the HCIMs Nat i ona l i t y , Mar i ta lS ta tus
, ContactPerson , He a l t hP r o f e s s i o n a l and
Hea l thca r eProv ide r (HCIM r e l e a s e s 2015 , 2016 and
2017) ” ,
” purpose ” : ” Pat i en t . Tracking a pa t i e n t i s the c en t e r
o f the h e a l t h c a r e p r o c e s s . Names and add r e s s e s are
a l s o in compl iance with HL7 V3 Bas ic Components . ” ,
” copy r i gh t ” : ”CC0” ,
” f h i rV e r s i o n ” : ” 3 . 0 . 1 ” ,
[ . . . ]
17The full profile can be viewed at https://simplifier.net/NictizSTU3/nl-core-patient/~json
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D.5. DE-Baseprofile Organisation
Figure 35: NL-Baseprofile Patient [78]
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D.6. DE-Baseprofile Organisation - JSON
The profile was cut, due to the amount of information and the length of the data18.
Listing 8: DE-Baseprofile Organisation
{
” resourceType ” : ” S t r u c t u r eD e f i n i t i o n ” ,
”meta ” : {
” lastUpdated ” : ”2017 -10 -20T11 : 01 : 1 5 . 1 67+02 : 00”
} ,
” u r l ” : ” http : // f h i r . de/ S t r u c t u r eD e f i n i t i o n / o rgan i z a t i on
- de - b a s i s / 0 . 2 ” ,
” v e r s i o n ” : ” 0 . 2 -WORK” ,
”name ” : ” o r gan i z a t i on - de - ba s i s - 0 . 2 ” ,
” t i t l e ” : ” Organ i sat ion , deut s che s B a s i s p r o f i l ( Vers ion
0 . 2 ) ” ,
” s t a t u s ” : ” d r a f t ” ,
” date ” : ”2018 -06 -28” ,
” pub l i s h e r ” : ”HL7 Deutschland e .V. ( Techn i sches Komitee
FHIR) ” ,
” contac t ” : [
{
” te lecom ” : [
{
” system ” : ” o the r ” ,
” va lue ” : ” http : // h l7 . de/ t e chn i s che -
komitees / f h i r /”
}
]
}
] ,
” d e s c r i p t i o n ” : ” B a s i s p r o f i l f ü r d i e Verwendung der
Organ i za t i on Ressource in Deutschland . ” ,
[ . . . ]
}
}
18The full profile can be viewed at https://simplifier.net/BasisprofilDE/organization-de-basis-0.2/~json
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E. Appendix: Slicing Example
The following example was taken out of the Simplifier Profiling Academy [46].
Listing 9: Slicing Example
<element id=”Medicat ionStatement . s ub j e c t ”>
<path va lue=”Medicat ionStatement . s ub j e c t ”/>
<s l i c i n g >
<d i s c r im ina t o r >
<type va lue=”type”/>
<path va lue=”$ t h i s ”/>
</d i s c r im ina t o r >
<r u l e s va lue=”open”/>
</ s l i c i n g >
<min va lue=”1”/> <max va lue=”1”/>
</element>
<element id=”Medicat ionStatement . s ub j e c t : Sub j e c tPa t i en t”>
<path va lue=”Medicat ionStatement . s ub j e c t ”/>
<sl iceName va lue=”Sub j e c tPa t i en t ”/>
<min va lue=”0”/> <max va lue=”1”/>
<type>
<code va lue=”Re f e r ence ”/>
<t a r g e t P r o f i l e va lue=”http : // h l7 . org / f h i r /
S t r u c t u r eD e f i n i t i o n / Pat i en t ”/>
</type>
</element>
<element id=”Medicat ionStatement . s ub j e c t : SubjectGroup”>
<path va lue=”Medicat ionStatement . s ub j e c t ”/>
<sl iceName va lue=”SubjectGroup”/>
<min va lue=”0”/> <max va lue=”1”/>
<type>
<code va lue=”Re f e r ence ”/>
<t a r g e t P r o f i l e va lue=”http : // h l7 . org / f h i r /
S t r u c t u r eD e f i n i t i o n /Group”/>
</type>
</element>
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F. Appendix: Customized Resource and Extension
Encounter ..
.extension ..
.extension.basedOn Extension ..1
Table 7: Profiling table of the ”Encounter” profile
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Listing 10: Differential of ”Encounter” resource
<d i f f e r e n t i a l >
<element id=”Encounter . e x t en s i on”>
<path va lue=”Encounter . e x t en s i on ” />
<s l i c i n g >
<d i s c r im ina t o r >
<type va lue=”va lue ” />
<path va lue=”u r l ” />
</d i s c r im ina t o r >
<r u l e s va lue=”open ” />
</ s l i c i n g >
</element>
<element id=”Encounter . e x t en s i on : MyExtension”>
<path va lue=”Encounter . e x t en s i on ” />
<sl iceName va lue=”basedOn” />
<sho r t va lue=”Opt iona l Extens ions Element ” />
<d e f i n i t i o n va lue=”Opt iona l Extens ion Element
- found in a l l r e s o u r c e s . ” />
<min va lue=”0” />
<max va lue=”*” />
<type>
<code va lue=”Extens ion ” />
<p r o f i l e va lue=”http : // example . org / f h i r /
S t r u c t u r eD e f i n i t i o n /MyExtension ” />
</type>
</element>
</ d i f f e r e n t i a l >
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G. Appendix: Proof of Concept
G.1. Appendix: Proof of Concept - ResearchStudy
Listing 11: Proof of Concept - ResearchStudy
<ResearchStudy>
<id va lue=”re s ea r chs tudy - soa -1” />
<meta>
<p r o f i l e va lue=”http : // c l i n i c a l s i t e . org / . . . ” />
</meta>
<i d e n t i f i e r >
<system va lue=”http : // c l i n i c a l s i t e . org / . . . ” />
<va lue va lue =”2157” />
</ i d e n t i f i e r >
<t i t l e va lue=”CLL2-BAG” />
<protoco l >
<r e f e r e n c e va lue=”P l anDe f i n i t i o n / p lande f - soa -1” />
</pro toco l >
<s t a t u s va lue=”in - p r o g r e s s ”>
<ex t en s i on u r l=”http : // c l i n i c a l s i t e . org / . . . ” >
<valueCode va lue=”2” />
</extens i on>
</sta tus>
<per iod> <s t a r t va lue =”2015 -05 -06” /> </per iod>
<sponsor>
<d i s p l a y va lue=”Un i v e r s i t ä t zu Köln” />
</sponsor>
<p r i n c i p a l I n v e s t i g a t o r >
<d i s p l a y va lue=”Dr . med . Paula Cramer” />
</p r i n c i p a l I n v e s t i g a t o r >
<s i t e >
<i d e n t i f i e r >
<system va lue=”http : // c l i n i c a l s i t e . org / . . . ” />
<va lue va lue=”53” />
</ i d e n t i f i e r >
</s i t e >
</ResearchStudy>
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G.2. Appendix: Proof of Concept - PlanDefinition
Listing 12: Proof of Concept - PlanDefinition
<PlanDe f i n i t i on >
<id va lue=”plande f - soa -1” />
<ve r s i o n va lue =”1.00” />
<name va lue=”Study p r o t o c o l f o r CLL2-BAG” />
<s t a t u s va lue=”d r a f t ” />
<exper imenta l va lue=”t rue ” />
<date va lue =”2018 -08 -07” />
<pub l i s h e r va lue=”Markus Döring ” />
<copyr i gh t va lue=”Medical Systems R&D group ” />
<act ion>
<t i t l e va lue=”GA101” />
<d e f i n i t i o n >
<r e f e r e n c e va lue=”Ac t i v i t yD e f i n i t i o n /
p l anned Inve s t i g a t i ona lDrug1 ” />
<d i s p l a y va lue=”GA101” />
</d e f i n i t i o n >
</act ion>
<act ion>
<t i t l e va lue=”ABT-199” />
<d e f i n i t i o n >
<r e f e r e n c e va lue=”Ac t i v i t yD e f i n i t i o n /
p l anned Inve s t i g a t i ona lDrug2 ” />
<d i s p l a y va lue=”ABT-199” />
</d e f i n i t i o n >
</act ion>
</P lanDe f i n i t i on >
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G.3. Appendix: Proof of Concept - ActivityDefinition
Listing 13: Proof of Concept - ActivityDefinition 1
<Ac t i v i t yDe f i n i t i o n >
<id va lue=”p l anned Inve s t i g a t i ona lDrug1 ” />
<name va lue=”planned I n v e s t i g a t i o n a l Drug GA101” />
<s t a t u s va lue=”d r a f t ” />
<exper imenta l va lue=”t rue ” />
<date va lue =”2018 -08 -07” />
<copyr i gh t va lue=”Medical Systems R&D group ” />
<productRefe rence>
<r e f e r e n c e va lue=”Medicat ion / i n v e s t i g a t i o n a lD rug1 ”
/>
<d i s p l a y va lue=”GA101” />
</productRefe rence>
<dosage>
<tex t va lue=”D1 mit 100mg” />
<timing>
<event va lue =”2015 -12 -04” />
</timing>
<doseQuantity>
<va lue va lue =”100” />
</doseQuantity>
</dosage>
<dosage>
<tex t va lue=”D2 mit 900mg” />
<timing>
<event va lue =”2015 -12 -05” />
</timing>
<doseQuantity>
<va lue va lue =”900” />
</doseQuantity>
</dosage>
. . .
</Ac t i v i t yDe f i n i t i o n >
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Listing 14: Proof of Concept - ActivityDefinition 2
<Ac t i v i t yDe f i n i t i o n >
<id va lue=”p l anned Inve s t i g a t i ona lDrug2 ” />
<name va lue=”planned I n v e s t i g a t i o n a l Drug ABT-199” />
<s t a t u s va lue=”d r a f t ” />
<exper imenta l va lue=”t rue ” />
<date va lue =”2018 -08 -07” />
<copyr i gh t va lue=”Medical Systems R&D group ” />
<productRefe rence>
<r e f e r e n c e va lue=”Medicat ion / i n v e s t i g a t i o n a lD rug2 ”
/>
<d i s p l a y va lue=”ABT-199” />
</productRefe rence>
<dosage>
<tex t va lue=”D1-7 mit 20mg” />
<timing>
<event va lue =”2016 -01 -07” />
<repeat>
<count va lue=”7” />
<frequency va lue=”1” />
<per i od va lue=”1” />
<per iodUni t va lue=”d” />
</repeat>
</timing>
<doseQuantity>
<va lue va lue=”20” />
</doseQuantity>
</dosage>
. . .
</Ac t i v i t yDe f i n i t i o n >
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G.4. Appendix: Proof of Concept - Medication
Listing 15: Proof of Concept - Medication 1
<Medication>
<id va lue=” i nv e s t i g a t i o n a lD rug 1 ” />
<code>
<coding>
<system va lue=”http : // snomed . i n f o / s c t ” />
<code va lue =”710287009” />
<d i s p l a y va lue=”GA101” />
</coding>
</code>
<s t a t u s va lue=”a c t i v e ” />
<form>
<coding>
<system va lue=”http : // snomed . i n f o / s c t ” />
<code va lue =”385229008” />
<d i s p l a y va lue=”IV - I n f u s i o n ” />
</coding>
</form>
</Medication>
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Listing 16: Proof of Concept - Medication 2
<Medication>
<id va lue=” i nv e s t i g a t i o n a lD rug 2 ” />
<code>
<coding>
<system va lue=”http : // snomed . i n f o / s c t ” />
<code va lue =”763511000” />
<d i s p l a y va lue=”ABT-199” />
</coding>
</code>
<s t a t u s va lue=”a c t i v e ” />
<form>
<coding>
<system va lue=”http : // snomed . i n f o / s c t ” />
<code va lue =”385022006” />
<d i s p l a y va lue=”Oral l i q u i d ” />
</coding>
</form>
</Medication>
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G.5. Appendix: Proof of Concept - Encounter
Listing 17: Proof of Concept - Encounter
<Encounter>
<id va lue=” s t u d y v i s i t 1 ” />
<ex t en s i on u r l=”ht tps : / / s i m p l i f i e r . net / t e s t20171092 /
re s ea r chs tudy - r e f e r e n c e ”>
<va lueRe fe r ence>
<r e f e r e n c e va lue=”ResearchStudy / re s ea r chs tudy -
soa -1” />
<d i s p l a y va lue=”CLL2-BAG” />
</va lueRe f e r ence>
</extens i on>
<s t a t u s va lue=”planned ” />
<c l a s s >
<system va lue=”http : // h l7 . org / f h i r /v3/ActCode” />
<code va lue=”AMB” />
<d i s p l a y va lue=”ambulatory ” />
</c l a s s >
<sub j e c t >
<r e f e r e n c e va lue=”Pat i en t /1” />
</sub j e c t >
<pa r t i c i p an t >
<ind i v i dua l >
<r e f e r e n c e va lue=”P r a c t i t i o n e r /150” />
</ ind i v i dua l >
</pa r t i c i p an t >
<length>
<va lue va lue=”30” />
<un i t va lue=”min” />
<system va lue=”http : // un i t s o fmeasu r e . org ” />
<code va lue=”min” />
</length>
</Encounter>
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G.6. Appendix: Proof of Concept - MedicationStatement
Listing 18: Proof of Concept - MedicationStatement
<Medicat ionStatement>
<id va lue=”medicat ions tatement1 ” />
<basedOn>
<r e f e r e n c e va lue=”Medicat ionRequest /
med i ca t i on r eque s t1 ” />
</basedOn>
<context>
<r e f e r e n c e va lue=”Encounter / s t u d y v i s i t 1 ” />
</context>
<s t a t u s va lue=”intended ” />
<medicat ionRe fe rence>
<r e f e r e n c e va lue=”Medicat ion / i n v e s t i g a t i o n a lD rug1 ”
/>
</medicat ionRe fe rence>
<dateAsse r t ed va lue =”2018 -08 -09” />
<sub j e c t >
<r e f e r e n c e va lue=”Pat i en t /1” />
</sub j e c t >
<taken va lue=”y” />
</Medicat ionStatement>
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G.7. Appendix: Proof of Concept - MedicationRequest
Listing 19: Proof of Concept - MedicationRequest
<Medicat ionRequest>
<id va lue=”med i ca t i on r eque s t1 ” />
<d e f i n i t i o n >
<r e f e r e n c e va lue=”Ac t i v i t yD e f i n i t i o n /
p l anned Inve s t i g a t i ona lDrug1 ” />
</d e f i n i t i o n >
<in t e n t va lue=”propo sa l ” />
<medicat ionRe fe rence>
<r e f e r e n c e va lue=”Medicat ion / i n v e s t i g a t i o n a lD rug1 ”
/>
</medicat ionRe fe rence>
<sub j e c t >
<r e f e r e n c e va lue=”Pat i en t /1” />
</sub j e c t >
<authoredOn va lue =”2018 -08 -09” />
<reque s t e r >
<agent>
<r e f e r e n c e va lue=”P r a c t i t i o n e r /150” />
</agent>
</reque s t e r >
</Medicat ionRequest>
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H. Appendix: Active Questionnaire Example
An example Questionnaire, create by Simone Heckmann, for the University Hospital
Cologne, based on the work of Grahame Grieve about active Questionnaires. [76]
Listing 20: Active Questionnaire Example
<Ques t i onna i r e xmlns=”http : // h l7 . org / f h i r ”>
<u r l va lue=”http : // uni - koe ln . de/ f h i r / Ques t i onna i r e /nNGM-
a c t i v e ” />
<t i t l e va lue=”nNGM ( a c t i v e ) ” />
<s t a t u s va lue=”d r a f t ” />
<date va lue =”2018 -08 -10” />
<subjectType va lue=”Pat i en t ” />
<item>
<ext en s i on u r l=”http : // h l7 . org / f h i r / S t r u c t u r eD e f i n i t i o n /
v a r i a b l e ”>
<va lueExpres s ion>
<name va lue=”smokeObs” />
<language va lue=”app l i c a t i o n /x - f h i r - query ” />
<exp r e s s i o n va lue=”Observat ion ? code=http : // l o i n c .
org |72166 -2” />
</va lueExpres s ion>
</extens i on>
<ex t en s i on u r l=”http : // h l7 . org / f h i r /
S t r u c t u r eD e f i n i t i o n / populate - va lue”>
<va lueExpres s ion>
<language va lue=”t ex t / fh i rPa th ” />
<exp r e s s i o n va lue=”smokeObs . va lue ” />
</va lueExpres s ion>
</extens i on>
. . .
</item>
</Quest ionna i r e>
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